BCL9L and urinary bladder cancer: NAT10 mediates ac4C modification of oncogenes (BCL9L, SOX4, and AKT1) in bladder cancer to enhance their mRNA stability, thereby promoting cancer cell malignant behaviors and stem-cell-like properties [16].